Why we focus on PV, ET and MF
The decision to focus on MF, PV and ET was made at the inception of the organization by our Board of Directors after much discussion with researchers, clinicians, and representatives from the patient community. We recognize that there are other blood diseases that are under the myeloproliferative neoplasms umbrella, but we are a small foundation and need to focus our resources, and for that reason focus only on the Philadelphia Chromosome Negative MPNs Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis.
However, we also work closely with many other organizations working to address research and patient needs. We have very strong partnerships with the Leukemia and Lymphoma Society, Patient Power, the National Organization for Rare Disorders (NORD) and many others. It is through these partnerships where we can help patients diagnosed with other MPNs other than MF, PV and ET.
We are proud that the research we have funded has also led to a better understanding of all blood cancers.